This inventor holds 38 USPTO granted patents and 10 published patent applications, plus 14 CIPO patents and 20 EPO patents, primarily in Single-Chain Proteins. Top assignees: Apogenix Ag, Apogenix Gmbh, Merck Serono S. a.. Active years: 2011-2022.
Location History:
- Shriesheim, DE (2012)
- Schriesheim, DE (2011 - 2022)
Company Filing History:
25 out of 27 
9 out of 11 
4 out of 145 
Years Active: 2011-2022
Areas of Expertise:
Title: Meinolf Thiemann: Innovator in Therapeutic Proteins
Introduction
Meinolf Thiemann, based in Schriesheim, Germany, is a prominent inventor with a remarkable portfolio of 38 patents. His work primarily focuses on the development of innovative therapeutic proteins, contributing significantly to the fields of medicine and biotechnology.
Latest Patents
Thiemann's latest patents include groundbreaking inventions such as "Light single-chain fusion polypeptides, encoding nucleic acid molecules and host cells." This invention refers to single-chain fusion proteins comprising three soluble TNF superfamily cytokine domains. These proteins are characterized by their non-aggregating nature, making them suitable for therapeutic, diagnostic, and research applications. Another notable patent is for "Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) receptor agonist proteins." These specific GITR receptor agonist proteins also feature nucleic acids and are designed to treat diseases or disorders associated with GITRL. Similar to his earlier inventions, these proteins also boast a non-aggregating quality and are applicable in therapeutic, diagnostic, and research contexts.
Career Highlights
Meinolf Thiemann has made significant contributions to the biotechnology industry, particularly during his tenures at notable companies such as Apogenix AG and Apogenix GmbH. His expertise in the development of therapeutic proteins has solidified his reputation as an innovator in the field.
Collaborations
Throughout his career, Thiemann has collaborated with esteemed colleagues, including Oliver Hill and Christian Gieffers. These partnerships have undoubtedly enhanced his research and contributed to the successful development of his patented technologies.
Conclusion
In summary, Meinolf Thiemann is a distinguished inventor whose work has advanced the field of therapeutic proteins significantly. His innovative patents reflect his dedication to developing solutions that offer therapeutic, diagnostic, and research applications. With a solid background in biotechnology and meaningful collaborations, Thiemann continues to impact the scientific community positively.